Total amount raised
Latest funding date
Location
Albert Cai is the CEO of Harbor, a clinical trial software company founded in 2025. With experience across the healthcare and medical device industries, he brings skills from financial analysis, product management, and biomedical engineering.
Who is Albert Cai?
Albert Cai, the CEO of Harbor, has a unique background that led to this role. He began his work in healthcare consulting where he covered diabetes technology companies in San Francisco as an analyst. He later joined Biolinq, an innovative medical device company, and helped bring their product from first-in-human clinical trials to FDA authorization: authoring regulatory submissions, developing algorithms, and helping run dozens of clinical trials from protocol development through data analysis. Under his leadership, Harbor has built innovative software to bring secure, compliant AI to clinical trial workflows.
Work History
Albert Cai has held many positions across the healthcare and medical device industries since starting his career:
- University of Michigan - Research Assistant (2016 to 2018)
- Close Concerns - Head of Diabetes Technology (2019 to 2021)
- Biolinq - Product Manager (2021 to 2025)
- Harbor - CEO (2025 to Present)
Education History
Albert Cai’s unique educational journey laid the roots for his career in healthcare and technology. He holds a Bachelor of Science degree in Biomedical Engineering from The University of Michigan, where he discovered his interest in healthcare and medical devices.
When did Albert Cai found Harbor?
Albert Cai founded Harbor in 2025. Harbor builds innovative, compliant, and secure software to run clinical trials more efficiently. Their first product is an AI-powered system-of-record, or EDC (electronic data capture) system that automates the transformation of clinical source data into a verified, compliant, FDA-ready package. The software automatically generates eCRFs and source documents from clinical trial protocols, automates source data entry to enable truly remote monitoring, and ensures full 21 CFR Part 11 compliance.
